For many biopharmas, it takes years of hard work to transition from being a clinical-stage drugmaker to a commercial one.

President-elect Donald Trump has put forward a formal pick for the top spot at the U.S. Food and Drug Administration. | ...

While Johnson & Johnson hopes to soon resolve more than 60,000 talc lawsuits with an $8 billion bankruptcy settlement in the ...

With Spanish plasma specialist Grifols turning down a potential multi-billion-dollar takeover bid, it’s likely back to the ...

As the biopharma industry braces for a second term under President-elect Donald Trump, speculation is swirling around the ...

While president-elect Donald Trump has already made his leadership picks for the Department of Health and Human Services (HHS ...

For Big Pharma, recent headlines out of China suggest multinational drugmakers are facing their share of challenges in the ...

Neurology patient groups have chided the pharma industry for investing too little into treating disorders of the nervous ...

Roche's spinal muscular atrophy (SMA) medicine Evrysdi only gained its FDA approval in 2020, but generics companies are ...

The new drug, Jazz Pharmaceuticals’ zanidatamab, has won an FDA accelerated approval for adults with previously treated ...

Every year, Fierce’s pharma, biotech, and medtech teams come together to spotlight some of the fiercest women in life s | ...

It was only last October that UCB’s up-and-coming immunology powerhouse Bimzelx first crossed the FDA finish line in ...